EUVIMEDEUVIMED entdecken
Kohortenstudie

Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study

Kevin Sheng-Kai Ma iD, Bethany Brumbaugh, Rebecca R Saff iD, Wanda Phipatanakul iD, Serena Yun-Chen Tsai iD, Mike Westmeijer, Allison Holt, Joseph Ebriani, Carlos A Camargo iD, Steven T Chen

European Respiratory Journal · 2025

DOI: 10.1183/13993003.00139-2025 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift European Respiratory Journal, 2025. Verfasst von Kevin Sheng-Kai Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA kevinskma1@gmail.com. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Lymphoma, Anti-Asthmatic Agents. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dupilumab is approved for the treatment of atopic dermatitis, asthma, and other allergic diseases. Recent studies suggest that patients with atopic dermatitis receiving dupilumab are at a higher risk of developing cutaneous lymphoma. This study aimed to investigate the risk of lymphoma among patients with asthma receiving dupilumab.

Methods

This population-based cohort study included patients in the United States with asthma who initiated dupilumab or the active comparator (combination therapy with inhaled corticosteroids (ICS) plus long-acting β-agonists (LABA), or ICS/LABA), between 2018 and 2024. Propensity score matching was used to balance baseline characteristics between groups. The primary outcome was new-onset lymphoma, and secondary outcomes included other malignancies and all-cause mortality.

Results

A total of 14 936 dupilumab-treated and 734 126 ICS/LABA-treated patients with asthma were included. After propensity score matching, dupilumab-treated patients were found to have a higher risk of lymphoma (54 versus 43 cases, hazard ratio (HR) 1.79, 95% CI 1.19–2.71), especially T-cell and natural killer (NK)-cell lymphomas (19 versus ≤10 cases, HR 4.58, 95% CI 1.82–11.53). There was no significant difference in incidence of other malignant neoplasms. Dupilumab was also associated with significantly lower all-cause mortality (328 versus 793 deaths, HR 0.65, 95% CI 0.57–0.74).

Conclusions

Dupilumab treatment was associated with lower all-cause mortality among patients with asthma, despite increased risk of lymphoma, particularly T-cell and NK-cell lymphomas. These findings highlight the need for long-term surveillance and further research into the immunological mechanisms underlying dupilumab-associated lymphoma in asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAntibodies, Monoclonal, HumanizedLymphomaAnti-Asthmatic AgentsHumansFemaleMaleMiddle AgedAdultPropensity ScoreAgedCohort StudiesUnited StatesAdrenal Cortex HormonesRetrospective Studies

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedAdrenal Cortex HormonesAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA kevinskma1@gmail.com.
  • Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • K.S-K. Ma, B. Brumbaugh, R.R. Saff, W. Phipatanakul and S.Y-C. Tsai contributed equally as first authors.
  • Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
  • Harvard Medical School, Boston, MA, USA.
  • Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.

ORCID-Profile: Kevin Sheng-Kai Ma, Rebecca R Saff, Wanda Phipatanakul, Serena Yun-Chen Tsai, Carlos A Camargo

Zitieren

APA

Ma, K. S., Brumbaugh, B., Saff, R. R., Phipatanakul, W., Tsai, S. Y., Westmeijer, M., Holt, A., Ebriani, J., Camargo, C. A., & Chen, S. T. (2025). Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study. European Respiratory Journal. https://doi.org/10.1183/13993003.00139-2025

Vancouver

Ma KS, Brumbaugh B, Saff RR, Phipatanakul W, Tsai SY, Westmeijer M, et al. Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study. European Respiratory Journal. 2025. doi:10.1183/13993003.00139-2025

BibTeX
@article{Ma2025,
  author = {Ma, Kevin Sheng-Kai and Brumbaugh, Bethany and Saff, Rebecca R and Phipatanakul, Wanda and Tsai, Serena Yun-Chen and Westmeijer, Mike and Holt, Allison and Ebriani, Joseph and Camargo, Carlos A and Chen, Steven T},
  title = {Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study},
  journal = {European Respiratory Journal},
  year = {2025},
  doi = {10.1183/13993003.00139-2025}
}
Kostenlos starten →